NYSE · HCA
HCA Healthcare, Inc.
$478.08+$14.86 (+3.21%)
HCA Healthcare, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.09% below the high.
Loading market information…
XETRA · FRE.DE · EUR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:36 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Fresenius SE & Co. KGaA’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Fresenius SE & Co. KGaA’s forward annual dividend is €1.05 per share, paid annual. The forward yield is 2.23% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Fresenius SE & Co. KGaA’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of €0.79. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Fresenius SE & Co. KGaA’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 7, 2025 | €0.84+12.94% vs estimate | €5.65B+8.07% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | €0.75+5.37% vs estimate | €5.63B+3.37% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | €0.69-2.82% vs estimate | €5.37B-0.95% vs estimate |
|---|
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$478.08+$14.86 (+3.21%)
HCA Healthcare, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.09% below the high.
$270.57+$2.07 (+0.77%)
Tenet Healthcare Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.41% below the high.
SAR 221.50-SAR 1.60 (-0.72%)
Dr. Sulaiman Al Habib Medical Services Group Company’s quoted price sits in the lower half of its reported 52-week range, 19.92% below the high.
MYR 7.85MYR 0.00 (0.0%)
IHH Healthcare Berhad’s quoted price sits in the lower half of its reported 52-week range, 25.1% below the high.
$193.31+$9.38 (+5.1%)
DaVita Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.89% below the high.
€41.47+€0.87 (+2.14%)
Fresenius Medical Care AG & Co. KGaA’s quoted price sits in the upper half of its reported 52-week range, 12.77% below the high.
$176.61+$4.43 (+2.57%)
Universal Health Services, Inc.’s quoted price sits in the lower half of its reported 52-week range, 28.3% below the high.
€14.30€0.00 (0.0%)
RHÖN-KLINIKUM Aktiengesellschaft’s quoted price sits in the upper half of its reported 52-week range, 8.92% below the high.
